A Phase 2b, Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Second- or Third-line Treatment of Subjects with Unresectable Pleural or Peritoneal Malignant Mesothelioma
Unresectable Pleural or Peritoneal Malignant Mesothelioma
18 Years - 99 Years
Endpoint Classification: Efficacy
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verified 01 Jan 2023 by MedImmune, LLC
No locations available
Tremelimumab is to be administered as an IV solution, followed by observation.
|Placebo Comparator: Placebo|
Placebo is to be administered as an IV solution, followed by observation.